Cargando…

The m(6)A methylation landscape, molecular characterization and clinical relevance in prostate adenocarcinoma

BACKGROUND: Despite the recent progress of therapeutic strategies in treating prostate cancer (PCa), the majority of patients still eventually relapse, experiencing dismal outcomes. Therefore, it is of utmost importance to identify novel viable targets to increase the effectiveness of treatment. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Chao, Peng, Dongyi, Gan, Yu, Zhou, Lei, Hou, Weibin, Wang, Bingzhi, Yuan, Peng, Xiong, Wei, Wang, Long
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10076583/
https://www.ncbi.nlm.nih.gov/pubmed/37033963
http://dx.doi.org/10.3389/fimmu.2023.1086907
_version_ 1785020159639945216
author Li, Chao
Peng, Dongyi
Gan, Yu
Zhou, Lei
Hou, Weibin
Wang, Bingzhi
Yuan, Peng
Xiong, Wei
Wang, Long
author_facet Li, Chao
Peng, Dongyi
Gan, Yu
Zhou, Lei
Hou, Weibin
Wang, Bingzhi
Yuan, Peng
Xiong, Wei
Wang, Long
author_sort Li, Chao
collection PubMed
description BACKGROUND: Despite the recent progress of therapeutic strategies in treating prostate cancer (PCa), the majority of patients still eventually relapse, experiencing dismal outcomes. Therefore, it is of utmost importance to identify novel viable targets to increase the effectiveness of treatment. The present study aimed to investigate the potential relationship between N6-methyladenosine (m6A) RNA modification and PCa development and determine its clinical relevance. METHODS: Through systematic analysis of the TCGA database and other datasets, we analyzed the gene expression correlation and mutation profiles of m6A-related genes between PCa and normal tissues. Patient samples were divided into high- and low-risk groups based on the results of Least Absolute Shrinkage and Selection Operator (LASSO) Cox analysis. Subsequently, differences in biological processes and genomic characteristics of the two risk groups were determined, followed by functional enrichment analysis and gene set enrichment (GSEA) analysis. Next, we constructed the protein-protein interaction (PPI) network of differentially expressed genes between patients in high- and low-risk groups, along with the mRNA-miRNA-lncRNA network. The correlation analysis of tumor-infiltrating immune cells was further conducted to reveal the differences in immune characteristics between the two groups. RESULTS: A variety of m6A-related genes were identified to be differentially expressed in PCa tissues as compared with normal tissues. In addition, the PPI network contained 278 interaction relationships and 34 m6A-related genes, and the mRNA-miRNA-lncRNA network contained 17 relationships, including 91 miRNAs. Finally, the immune characteristics analysis showed that compared with the low-risk group, the levels of M1 and M2 macrophages in the high-risk group significantly increased, while the levels of mast cells resting and T cells CD4 memory resting significantly decreased. CONCLUSIONS: This study provides novel findings that can further the understanding of the role of m6A methylation during the progression of PCa, which may facilitate the invention of targeted therapeutic drugs.
format Online
Article
Text
id pubmed-10076583
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100765832023-04-07 The m(6)A methylation landscape, molecular characterization and clinical relevance in prostate adenocarcinoma Li, Chao Peng, Dongyi Gan, Yu Zhou, Lei Hou, Weibin Wang, Bingzhi Yuan, Peng Xiong, Wei Wang, Long Front Immunol Immunology BACKGROUND: Despite the recent progress of therapeutic strategies in treating prostate cancer (PCa), the majority of patients still eventually relapse, experiencing dismal outcomes. Therefore, it is of utmost importance to identify novel viable targets to increase the effectiveness of treatment. The present study aimed to investigate the potential relationship between N6-methyladenosine (m6A) RNA modification and PCa development and determine its clinical relevance. METHODS: Through systematic analysis of the TCGA database and other datasets, we analyzed the gene expression correlation and mutation profiles of m6A-related genes between PCa and normal tissues. Patient samples were divided into high- and low-risk groups based on the results of Least Absolute Shrinkage and Selection Operator (LASSO) Cox analysis. Subsequently, differences in biological processes and genomic characteristics of the two risk groups were determined, followed by functional enrichment analysis and gene set enrichment (GSEA) analysis. Next, we constructed the protein-protein interaction (PPI) network of differentially expressed genes between patients in high- and low-risk groups, along with the mRNA-miRNA-lncRNA network. The correlation analysis of tumor-infiltrating immune cells was further conducted to reveal the differences in immune characteristics between the two groups. RESULTS: A variety of m6A-related genes were identified to be differentially expressed in PCa tissues as compared with normal tissues. In addition, the PPI network contained 278 interaction relationships and 34 m6A-related genes, and the mRNA-miRNA-lncRNA network contained 17 relationships, including 91 miRNAs. Finally, the immune characteristics analysis showed that compared with the low-risk group, the levels of M1 and M2 macrophages in the high-risk group significantly increased, while the levels of mast cells resting and T cells CD4 memory resting significantly decreased. CONCLUSIONS: This study provides novel findings that can further the understanding of the role of m6A methylation during the progression of PCa, which may facilitate the invention of targeted therapeutic drugs. Frontiers Media S.A. 2023-03-23 /pmc/articles/PMC10076583/ /pubmed/37033963 http://dx.doi.org/10.3389/fimmu.2023.1086907 Text en Copyright © 2023 Li, Peng, Gan, Zhou, Hou, Wang, Yuan, Xiong and Wang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Li, Chao
Peng, Dongyi
Gan, Yu
Zhou, Lei
Hou, Weibin
Wang, Bingzhi
Yuan, Peng
Xiong, Wei
Wang, Long
The m(6)A methylation landscape, molecular characterization and clinical relevance in prostate adenocarcinoma
title The m(6)A methylation landscape, molecular characterization and clinical relevance in prostate adenocarcinoma
title_full The m(6)A methylation landscape, molecular characterization and clinical relevance in prostate adenocarcinoma
title_fullStr The m(6)A methylation landscape, molecular characterization and clinical relevance in prostate adenocarcinoma
title_full_unstemmed The m(6)A methylation landscape, molecular characterization and clinical relevance in prostate adenocarcinoma
title_short The m(6)A methylation landscape, molecular characterization and clinical relevance in prostate adenocarcinoma
title_sort m(6)a methylation landscape, molecular characterization and clinical relevance in prostate adenocarcinoma
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10076583/
https://www.ncbi.nlm.nih.gov/pubmed/37033963
http://dx.doi.org/10.3389/fimmu.2023.1086907
work_keys_str_mv AT lichao them6amethylationlandscapemolecularcharacterizationandclinicalrelevanceinprostateadenocarcinoma
AT pengdongyi them6amethylationlandscapemolecularcharacterizationandclinicalrelevanceinprostateadenocarcinoma
AT ganyu them6amethylationlandscapemolecularcharacterizationandclinicalrelevanceinprostateadenocarcinoma
AT zhoulei them6amethylationlandscapemolecularcharacterizationandclinicalrelevanceinprostateadenocarcinoma
AT houweibin them6amethylationlandscapemolecularcharacterizationandclinicalrelevanceinprostateadenocarcinoma
AT wangbingzhi them6amethylationlandscapemolecularcharacterizationandclinicalrelevanceinprostateadenocarcinoma
AT yuanpeng them6amethylationlandscapemolecularcharacterizationandclinicalrelevanceinprostateadenocarcinoma
AT xiongwei them6amethylationlandscapemolecularcharacterizationandclinicalrelevanceinprostateadenocarcinoma
AT wanglong them6amethylationlandscapemolecularcharacterizationandclinicalrelevanceinprostateadenocarcinoma
AT lichao m6amethylationlandscapemolecularcharacterizationandclinicalrelevanceinprostateadenocarcinoma
AT pengdongyi m6amethylationlandscapemolecularcharacterizationandclinicalrelevanceinprostateadenocarcinoma
AT ganyu m6amethylationlandscapemolecularcharacterizationandclinicalrelevanceinprostateadenocarcinoma
AT zhoulei m6amethylationlandscapemolecularcharacterizationandclinicalrelevanceinprostateadenocarcinoma
AT houweibin m6amethylationlandscapemolecularcharacterizationandclinicalrelevanceinprostateadenocarcinoma
AT wangbingzhi m6amethylationlandscapemolecularcharacterizationandclinicalrelevanceinprostateadenocarcinoma
AT yuanpeng m6amethylationlandscapemolecularcharacterizationandclinicalrelevanceinprostateadenocarcinoma
AT xiongwei m6amethylationlandscapemolecularcharacterizationandclinicalrelevanceinprostateadenocarcinoma
AT wanglong m6amethylationlandscapemolecularcharacterizationandclinicalrelevanceinprostateadenocarcinoma